Skip to content
Inciteful Med

The Science of GSD IV: Why It Happens and How It Differs

Last updated:

Glycogen Storage Disease Type IV (GSD IV) is a rare genetic disorder caused by mutations in the GBE1 gene. This prevents the body from properly branching glycogen, causing abnormal sugar clumps called polyglucosan bodies to build up and damage the liver, muscles, and nerves.

Key Takeaways

  • • GSD IV is caused by mutations in the GBE1 gene, which provides instructions for the glycogen branching enzyme.
  • • Without this enzyme, the body creates abnormal, unbranched sugar clumps called polyglucosan bodies that damage cells.
  • • The condition is inherited in an autosomal recessive pattern, meaning a patient must inherit a mutated gene from both parents.
  • • In adults, GSD IV is frequently misdiagnosed as other neurological conditions like Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS).
  • • Confirming a GSD IV diagnosis requires genetic testing for GBE1 mutations and checking enzyme activity levels.

Glycogen Storage Disease Type IV (GSD IV), also known as Andersen disease, is a rare metabolic disorder that changes how the body handles sugar [1][2]. Unlike other types of GSD, which often involve too much normal glycogen, GSD IV involves the production of abnormal glycogen that the body cannot use or break down properly [1].

The Biology of GBE1 and “The Branching Problem”

To understand GSD IV, it helps to think of glycogen as a “sugar tree.” In a healthy person, the GBE1 gene provides instructions for an enzyme called the glycogen branching enzyme [3][4]. This enzyme acts like a gardener that creates many branches on the glycogen tree. These branches make the sugar easy to store compactly in our cells and quick to “harvest” when the body needs energy [5].

In GSD IV, this enzyme is missing or doesn’t work correctly. Without “branches,” the sugar chains grow too long and straight, looking more like starch found in plants (called amylopectin) than normal human glycogen [1][3].

How Polyglucosan Bodies Damage Cells

Because these long sugar chains are straight rather than branched, they cannot dissolve in the cell’s fluid. Instead, they clump together to form “stones” called polyglucosan bodies [5][6]. These bodies cause damage in several ways:

  • Mechanical Injury: Large clumps can physically crowd and eventually rupture the cell, leading to cell death (necrosis) [6].
  • Enzyme Trapping: These bodies act like “magnets,” sticking to and trapping other important enzymes the cell needs to function [7][8].
  • Metabolic Stress: The presence of these bodies causes the cell to undergo oxidative stress, essentially “clogging” the cell’s energy-producing machinery [9][10].

Why It Occurs: Autosomal Recessive Inheritance

GSD IV is an autosomal recessive condition [3]. This means a person must inherit two changed (mutated) copies of the GBE1 gene—one from each parent—to have the disease [3][4].

  • Carriers: Parents are typically “carriers,” meaning they have one changed gene and one normal gene. Carriers do not usually have any symptoms [3].
  • Recurrence Risk: For two carrier parents, there is a 25% (1 in 4) chance with each pregnancy that the child will have GSD IV [3][11].
  • Family Testing: Because this is an inherited condition, genetic counseling is highly recommended. Siblings of the patient have a 25% chance of also having the condition and a 50% chance of being carriers. Extended family members may also wish to pursue carrier testing.

Distinguishing GSD IV from Other Conditions

Because GSD IV can affect the liver, muscles, and nerves, it is often mistaken for other diseases. Doctors use a differential diagnosis process to rule out similar-looking conditions.

Comparison with Other Glycogen Storage Diseases

While all GSDs involve sugar metabolism, their “signatures” differ [12]:

  • GSD I (von Gierke): Primarily affects the liver and causes severe low blood sugar (hypoglycemia) from birth. (In GSD IV, low blood sugar is usually a late complication, not an early symptom) [13][14].
  • GSD II (Pompe): A “lysosomal” disorder where glycogen builds up inside a specific part of the cell, often causing a severely enlarged heart [15][16].
  • GSD III (Cori/Forbes): Caused by a “debranching” enzyme deficiency; it can look like GSD IV but usually doesn’t involve the abnormal amylopectin-like bodies [2].

GSD IV vs. Conditions with Similar Storage

There are other rare diseases that also form polyglucosan bodies, but they have different genetic causes:

  • RBCK1 Deficiency: Often includes autoinflammation (frequent fevers) and immune system problems that are not typical in GSD IV [6][17].
  • Lafora Disease: Primarily affects the brain, causing severe epilepsy (seizures) and rapid mental decline in teenagers [18][19].

GSD IV vs. ALS and MS (Adult-Onset)

In adults, the form of GSD IV called Adult Polyglucosan Body Disease (APBD) is frequently misdiagnosed as Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) because they all involve progressive walking difficulties [20][21].

Feature APBD (GSD IV) ALS MS
Bladder Issues Very common early symptom (neurogenic bladder) [20] Rare as an early symptom [20] Common, but usually occurs with other “flares” [20]
Nerve Damage Affects both sensation (numbness) and movement [20] Primarily affects movement only [20] Caused by loss of nerve “insulation” (myelin) [20]
Imaging (MRI) Shows shrinking of the spinal cord and diffuse white matter changes [22] Often normal early on Shows specific “plaques” or spots of inflammation [20]

Confirming GSD IV usually requires genetic testing for GBE1 mutations and checking enzyme activity levels [23][21].

Next: Learn how these biological changes cause symptoms in the Clinical Continuum.

Frequently Asked Questions

What causes Glycogen Storage Disease Type IV?
GSD IV is caused by mutations in the GBE1 gene. This gene provides instructions for the glycogen branching enzyme, which is essential for the body to pack and store sugar properly in our cells.
How is GSD IV inherited?
It is an autosomal recessive condition, meaning a person must inherit two mutated copies of the GBE1 gene, one from each parent. Parents who carry just one mutated copy are called carriers and typically do not have any symptoms.
What is the chance my child will have GSD IV if both parents are carriers?
If both parents are carriers of the mutated GBE1 gene, there is a 25 percent chance with each pregnancy that their child will be born with GSD IV. There is a 50 percent chance the child will be a carrier, like the parents.
What are polyglucosan bodies?
Polyglucosan bodies are clumps of abnormal, unbranched sugar chains that cannot dissolve in a cell's fluid. They build up inside cells and cause damage by physically crowding the cell, trapping important enzymes, and creating severe metabolic stress.
How is adult-onset GSD IV different from ALS or MS?
While adult-onset GSD IV (often called APBD) shares symptoms like walking difficulties with ALS and MS, it often involves early bladder issues and affects both physical sensation and movement. Doctors use genetic testing for the GBE1 mutation to confirm the exact diagnosis.

Questions for Your Doctor

  • • Based on my (or my child's) genetic results, are there any known clinical reports matching this specific mutation?
  • • Are there other family members we should notify about testing for carrier status or the disease itself?
  • • Can you provide a referral for a genetic counselor to help us understand the recurrence risks?
  • • If this is an adult diagnosis, can we be absolutely certain we have ruled out multiple sclerosis or ALS based on these genetic findings?

Questions for You

  • • Do you have a clear understanding of what it means to be a carrier versus having the condition?
  • • Is there a family history of undefined neurological issues, liver disease, or miscarriages that might be related?
  • • If you were misdiagnosed in the past, what were the conditions doctors suspected before finding GSD IV?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Liver Transplantation for Glycogen Storage Disease Type IV.

    Liu M, Sun LY

    Frontiers in pediatrics 2021; (9()):633822 doi:10.3389/fped.2021.633822.

    PMID: 33681109
  2. 2

    Update on polyglucosan storage diseases.

    Cenacchi G, Papa V, Costa R, et al.

    Virchows Archiv : an international journal of pathology 2019; (475(6)):671-686 doi:10.1007/s00428-019-02633-6.

    PMID: 31363843
  3. 3

    Severe neuromuscular forms of glycogen storage disease type IV: Histological, clinical, biochemical, and molecular findings in a large French case series.

    Lefèvre CR, Collardeau-Frachon S, Streichenberger N, et al.

    Journal of inherited metabolic disease 2024; (47(2)):255-269 doi:10.1002/jimd.12692.

    PMID: 38012812
  4. 4

    Case report: Familial glycogen storage disease type IV caused by novel compound heterozygous mutations in a glycogen branching enzyme 1 gene.

    Li Y, Tian C, Huang S, et al.

    Frontiers in genetics 2022; (13()):1033944 doi:10.3389/fgene.2022.1033944.

    PMID: 36425069
  5. 5

    Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.

    Nitschke S, Sullivan MA, Mitra S, et al.

    Brain : a journal of neurology 2022; (145(7)):2361-2377 doi:10.1093/brain/awac017.

    PMID: 35084461
  6. 6

    Myofiber-type-dependent 'boulder' or 'multitudinous pebble' formations across distinct amylopectinoses.

    Mitra S, Chen B, Shelton JM, et al.

    Acta neuropathologica 2024; (147(1)):46 doi:10.1007/s00401-024-02698-x.

    PMID: 38411740
  7. 7

    Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency.

    Thomsen C, Malfatti E, Jovanovic A, et al.

    Neuropathology and applied neurobiology 2022; (48(1)):e12761 doi:10.1111/nan.12761.

    PMID: 34405429
  8. 8

    Proteomic investigations of adult polyglucosan body disease: insights into the pathobiology of a neurodegenerative disorder.

    Abraham JR, Allen FM, Barnard J, et al.

    Frontiers in neurology 2023; (14()):1261125 doi:10.3389/fneur.2023.1261125.

    PMID: 38033781
  9. 9

    Alteration of mitochondrial function in the livers of mice with glycogen branching enzyme deficiency.

    Malinska D, Testoni G, Bejtka M, et al.

    Biochimie 2021; (186()):28-32 doi:10.1016/j.biochi.2021.04.001.

    PMID: 33857563
  10. 10

    Hallmarks of oxidative stress in the livers of aged mice with mild glycogen branching enzyme deficiency.

    Malinska D, Testoni G, Duran J, et al.

    Archives of biochemistry and biophysics 2020; (695()):108626 doi:10.1016/j.abb.2020.108626.

    PMID: 33049291
  11. 11

    Clinical phenotype and trio whole exome sequencing data from a patient with glycogen storage disease IV in Indonesia.

    Harsono IW, Ariani Y, Benyamin B, et al.

    Data in brief 2025; (58()):111231 doi:10.1016/j.dib.2024.111231.

    PMID: 39840231
  12. 12

    Molecular diagnosis of glycogen storage disease type I: a review.

    Beyzaei Z, Geramizadeh B

    EXCLI journal 2019; (18()):30-46.

    PMID: 30956637
  13. 13

    Computed Tomography and Magnetic Resonance Imaging Features of Primary and Secondary Hepatic Glycogenosis.

    Chen ZY, Liu YP, Zheng GJ

    Annals of hepatology 2018; (17(6)):903-905 doi:10.5604/01.3001.0012.7189.

    PMID: 30600303
  14. 14

    Assessment of auditory functions in patients with hepatic glycogen storage diseases.

    Şanlı ME, Gökay NY, Tutar H, et al.

    The Turkish journal of pediatrics 2022; (64(4)):658-670.

    PMID: 36082640
  15. 15

    ANESTHESIA MANAGEMENT IN AN INFANT WITH GLYCOGEN STORAGE DISEASE TYPE II (POMPE DISEASE).

    Al Atassi A, Al Zughaibi N, Naeim A, et al.

    Middle East journal of anaesthesiology 2015; (23(3)):343-6.

    PMID: 26860026
  16. 16

    Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.

    Meena NK, Raben N

    Biomolecules 2020; (10(9)) doi:10.3390/biom10091339.

    PMID: 32962155
  17. 17

    Unraveling a history of overlap: A phenotypic comparison of RBCK1-related disease and glycogen storage disease type IV.

    Crane HM, Asher S, Conway L, et al.

    American journal of medical genetics. Part A 2024; (194(7)):e63574 doi:10.1002/ajmg.a.63574.

    PMID: 38436530
  18. 18

    GYS1 or PPP1R3C deficiency rescues murine adult polyglucosan body disease.

    Chown EE, Wang P, Zhao X, et al.

    Annals of clinical and translational neurology 2020; (7(11)):2186-2198 doi:10.1002/acn3.51211.

    PMID: 33034425
  19. 19

    AAV-Mediated Artificial miRNA Reduces Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.

    Gumusgoz E, Kasiri S, Guisso DR, et al.

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022; (19(3)):982-993 doi:10.1007/s13311-022-01218-7.

    PMID: 35347645
  20. 20

    Frequent misdiagnosis of adult polyglucosan body disease.

    Hellmann MA, Kakhlon O, Landau EH, et al.

    Journal of neurology 2015; (262(10)):2346-51 doi:10.1007/s00415-015-7859-4.

    PMID: 26194201
  21. 21

    Diagnosis and management of glycogen storage disease type IV, including adult polyglucosan body disease: A clinical practice resource.

    Koch RL, Soler-Alfonso C, Kiely BT, et al.

    Molecular genetics and metabolism 2023; (138(3)):107525 doi:10.1016/j.ymgme.2023.107525.

    PMID: 36796138
  22. 22

    Adult polyglucosan body disease: an acute presentation leading to unmasking of this rare disorder.

    Johal J, Castro Apolo R, Johnson MW, et al.

    Hospital practice (1995) 2022; (50(3)):244-250 doi:10.1080/21548331.2021.1874182.

    PMID: 33412965
  23. 23

    Glycogen Storage Disease Type IV: A Rare Cause for Neuromuscular Disorders or Often Missed?

    Schene IF, Korenke CG, Huidekoper HH, et al.

    JIMD reports 2019; (45()):99-104 doi:10.1007/8904_2018_148.

    PMID: 30569318

This page explains the biology and genetics of GSD IV for educational purposes. Always consult your genetic counselor, neurologist, or physician to interpret specific genetic test results.

Stay up to date

Get notified when new research about Glycogen Storage Disease Type IV is published.

No spam. Unsubscribe anytime.